PMC:7696151 / 104568-104883
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 4027 | 286-289 | Gene | denotes | CD4 | Gene:920 |
| 4045 | 88-96 | Species | denotes | patients | Tax:9606 |
| 4116 | 98-101 | Chemical | denotes | HCQ | MESH:D006886 |
| 4117 | 113-124 | Chemical | denotes | hydroxyurea | MESH:D006918 |
| 4118 | 136-146 | Chemical | denotes | didanosine | MESH:D016049 |
| 4167 | 73-87 | Disease | denotes | HIV-1 infected | MESH:D015658 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T713 | 0-315 | Sentence | denotes | Paton, et al. (2002) [19] non-comparative clinical study22 asymptomatic HIV-1 infected patients HCQ (200 mg) + hydroxyurea (500 mg) + didanosine (125–200 mg), taken twice daily.48 weeks In the 12th week there was a significant reduction of 1.3 log10 in viral load and an increase in CD4+ percentage by mean 4.3%. |